<SEC-DOCUMENT>0001123292-25-000115.txt : 20250305
<SEC-HEADER>0001123292-25-000115.hdr.sgml : 20250305
<ACCEPTANCE-DATETIME>20250305170040
ACCESSION NUMBER:		0001123292-25-000115
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250305
DATE AS OF CHANGE:		20250305

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90423
		FILM NUMBER:		25712220

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13D/A</submissionType>
<previousAccessionNumber>0001104659-24-008866</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0000882095</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>4</amendmentNo>
<securitiesClassTitle>Common Stock, par value $0.0001</securitiesClassTitle>
<dateOfEvent>02/18/2025</dateOfEvent>
<previouslyFiledFlag>false</previouslyFiledFlag>
<issuerInfo>
<issuerCIK>0001724521</issuerCIK>
<issuerCUSIP>03969F109</issuerCUSIP>
<issuerName>Arcus Biosciences, Inc.</issuerName>
<address>
<com:street1>333 Lakeside Drive</com:street1>
<com:city>Foster City</com:city>
<com:stateOrCountry>CA</com:stateOrCountry>
<com:zipCode>94404</com:zipCode>
</address>
</issuerInfo>
<authorizedPersons>
<notificationInfo>
<personName>Gilead Sciences, Inc.</personName>
<personPhoneNum>650-574-3000</personPhoneNum>
<personAddress>
<com:street1>333 Lakeside Drive</com:street1>
<com:city>Foster City</com:city>
<com:stateOrCountry>CA</com:stateOrCountry>
<com:zipCode>94404</com:zipCode>
</personAddress>
</notificationInfo>
</authorizedPersons>
</coverPageHeader>
<reportingPersons>
<reportingPersonInfo>
<reportingPersonCIK>0000882095</reportingPersonCIK>
<reportingPersonName>GILEAD SCIENCES, INC.</reportingPersonName>
<fundType>OO</fundType>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<soleVotingPower>39691649</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>39691649</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
<aggregateAmountOwned>39691649</aggregateAmountOwned>
<isAggregateExcludeShares>N</isAggregateExcludeShares>
<percentOfClass>35</percentOfClass>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<commentContent>The number of shares reported in rows 7, 9, and 11 consists of (i) 2,200,000 shares of the common stock, par value $0.0001 per share (the "Common Stock"), of Arcus Biosciences, Inc. (the "Issuer") purchased in the 2020 Public Offering (as defined below), (ii) the initial purchase of 5,963,029 shares of Common Stock pursuant to a Common Stock Purchase Agreement, dated May 27, 2020, between Gilead Sciences, Inc. and the Issuer (the "Purchase Agreement"), (iii) the subsequent purchase of 5,650,000 shares of Common Stock pursuant to an Amended and Restated Common Stock Purchase Agreement, dated January 31, 2021, between Gilead Sciences, Inc. and the Issuer (the "Amended and Restated Purchase Agreement"), (iv) the subsequent purchase of 1,010,000 shares of Common Stock pursuant to a Second Amended and Restated Common Stock Purchase Agreement (the "Second Amended and Restated Purchase Agreement"), (v) the subsequent purchase of 15,238,095 shares of Common Stock of the Issuer pursuant to a Third Amended and Restated Common Stock Purchase Agreement (the "Third Amended and Restated Purchase Agreement"), (vi) the subsequent purchase of 1,363,636 shares of Common Stock pursuant to the Public Offering (as defined below), and (vii) the number of shares of Common Stock that would result in Gilead Sciences, Inc. holding 35% of the Issuer's then-outstanding Common Stock pursuant to a five-year option to purchase additional shares of Common Stock contained in the Third Amended and Restated Purchase Agreement (the "Option Shares"). Based upon 105,137,824 shares of Common Stock of the Issuer issued and outstanding upon the closing of the Public Offering, as disclosed in the prospectus supplement (the "Prospectus Supplement") filed with the Securities and Exchange Commission (the "SEC") on February 18, 2025 pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended, the number of Option Shares is currently equal to 8,266,889.&#13;
&#13;
The percent reported in row 13 is calculated based upon 113,404,713 shares of Common Stock issued and outstanding, based on 105,137,824 shares of Common Stock issued and outstanding upon the closing of the Public Offering, as disclosed in the Prospectus Supplement, and assuming the immediate exercise in full by Gilead of its option to purchase the Option Shares.</commentContent>
</reportingPersonInfo>
</reportingPersons>
<items1To7>
<item1>
<securityTitle>Common Stock, par value $0.0001</securityTitle>
<issuerName>Arcus Biosciences, Inc.</issuerName>
<issuerPrincipalAddress>
<com:street1>333 Lakeside Drive</com:street1>
<com:city>Foster City</com:city>
<com:stateOrCountry>CA</com:stateOrCountry>
<com:zipCode>94404</com:zipCode>
</issuerPrincipalAddress>
<commentText>This Amendment No. 4 (the "Amendment") amends the initial Schedule 13D filed by the Reporting Person on July 17, 2020, as amended by Amendment No. 1 to Schedule 13D filed with the SEC by the Reporting Person on February 2, 2021, Amendment No. 2 to Schedule 13D filed with the SEC by the Reporting Person on July 6, 2023, and Amendment No. 3 to Schedule 13D filed with the SEC by the Reporting Person on January 31, 2024. The Amendment was timely filed on February 20, 2025, but Schedule I to the Amendment was improperly filed as correspondence instead of as an exhibit to the Amendment. The Amendment is hereby refiled to correctly file Schedule I as an exhibit to the Amendment. The information contained in this Amendment is unchanged from that filed on February 20, with the exception of this Explanatory Note.</commentText>
</item1>
<item2>
<filingPersonName>This Schedule 13D is being filed by Gilead Sciences, Inc., a Delaware corporation ("Gilead" or the "Reporting Person").</filingPersonName>
<principalBusinessAddress>The principal business address of the Reporting Person is 333 Lakeside Drive, Foster City, California 94404.</principalBusinessAddress>
<principalJob>The principal business of the Reporting Person is to develop and commercialize innovative medicines in areas of unmet medical need and engage in any other activity or business lawfully carried on by a corporation organized under the laws of the State of Delaware. &#13;
&#13;
The directors and executive officers of the Reporting Person are set forth on Schedule I, attached hereto.  Schedule I sets forth the following information with respect to each such person:&#13;
&#13;
(i)	name;&#13;
(ii)	business address;&#13;
(iii)	position with the Reporting Person and present principal occupation or employment and, for persons not employed by the Reporting Person, the name, principal business and address of any corporation or other organization in which such employment is conducted; and&#13;
(iv)	citizenship.</principalJob>
<hasBeenConvicted>During the last five years, neither the Reporting Person nor any person named in Schedule I has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.</hasBeenConvicted>
<convictionDescription>See Item 2(d).</convictionDescription>
<citizenship>The jurisdiction of organization of the Reporting Person is set forth in subsection (a) above. The citizenship of each of the individuals referred to in Schedule I is set forth on Schedule I.</citizenship>
</item2>
<item3>
<fundsSource>Gilead acquired from the Issuer 2,200,000 shares of Common Stock in the Issuer's public offering (the "2020 Public Offering") at the public offering price of $27.50 per share.  The 2020 Public Offering was completed on June 2, 2020.  The total consideration paid by Gilead for these shares of Common Stock was $60,500,000, and such consideration was obtained from the available cash resources of Gilead.  &#13;
&#13;
	On May 27, 2020, Gilead entered into the Purchase Agreement (as defined below) pursuant to which Gilead agreed to purchase an initial 5,963,029 shares of the Issuer's Common Stock (the "Initial Purchase") at a purchase price of $33.54 per share (the "Initial Purchase Price"), which purchase occurred on July 13, 2020.  The total consideration for the Initial Purchase was $199,999,992.66, and such consideration was obtained from the available cash resources of Gilead.  &#13;
&#13;
	On January 31, 2021, Gilead entered into the Amended and Restated Purchase Agreement (as defined below) pursuant to which Gilead agreed to purchase an additional 5,650,000 shares of the Issuer's Common Stock (the "Second Purchase") at a purchase price of $39.00 per share (the "Second Purchase Price"), which purchase occurred on February 1, 2021.  The total consideration for the Second Purchase was $230,350,000.00, and such consideration was obtained from the available cash resources of Gilead.  &#13;
&#13;
	On June 27, 2023, Gilead entered into the Second Amended and Restated Purchase Agreement (as defined below) pursuant to which Gilead agreed to purchase an additional 1,010,000 shares of the Issuer's Common Stock (the "Third Purchase") at a purchase price of $19.26 per share (the "Third Purchase Price"), which purchase occurred on June 28, 2023. The total consideration for the Third Purchase was $19,452,600, and such consideration was obtained from the available cash resources of Gilead.&#13;
&#13;
	On January 29, 2024, Gilead entered into the Third Amended and Restated Purchase Agreement (as defined below) pursuant to which Gilead agreed to purchase an additional 15,238,095 shares of the Issuer's Common Stock (the "Fourth Purchase") at a purchase price of $21.00 per share (the "Fourth Purchase Price"), which purchase occurred on January 29, 2024.  The total consideration for the Fourth Purchase was $320,000,000, and such consideration was obtained from the available cash resources of Gilead.  Under the Third Amended and Restated Purchase Agreement, Gilead also has the right, at its option, to purchase additional shares from the Issuer, up to a maximum of 35% of the Issuer's then-outstanding Common Stock, from time to time for a period of five years from the closing of the Initial Purchase, at a purchase price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) at the time Gilead exercises such option and the Initial Purchase Price.  It is expected that the total consideration paid in connection with any exercise of such option will be obtained from the available cash resources of Gilead.  In addition, pursuant to the Amended and Restated Investor Rights Agreement (as defined below), Gilead has the right to designate three individuals to be appointed to the Issuer's board of directors.&#13;
&#13;
	On February 18, 2025, Gilead acquired from the Issuer 1,363,636 shares of Common Stock in the Issuer's most recent public offering (the "Public Offering") at the public offering price of $11.00 per share.  The Public Offering was completed on February 19, 2025.  The total consideration paid by Gilead for these shares of Common Stock was $14,999,996, and such consideration was obtained from the available cash resources of Gilead.</fundsSource>
</item3>
<item4>
<transactionPurpose>On May 27, 2020, Gilead and the Issuer entered into an Option, License and Collaboration Agreement (the "Collaboration Agreement") pursuant to with Gilead obtained an exclusive option to acquire an exclusive license to all of the Issuer's current and future clinical programs during the 10-year collaboration term and, for those programs that enter clinical development prior to the end of the collaboration term, for up to an additional three years thereafter.  &#13;
&#13;
	In addition to the Collaboration Agreement, Gilead and the Issuer entered into a Common Stock Purchase Agreement (the "Purchase Agreement"), which was amended and restated on January 31, 2021 to account for the Second Purchase (the "Amended and Restated Purchase Agreement"), on June 27, 2023 to account for the Third Purchase (the "Second Amended and Restated Purchase Agreement"), and on January 29, 2024 to account for the Fourth Purchase (the "Third Amended and Restated Purchase Agreement") and an Investor Rights Agreement (as amended by Amendment No. 1 thereto, which was subsequently amended and restated on January 29, 2024, the "Amended and Restated Investor Rights Agreement" and, together with the Third Amended and Restated Purchase Agreement, the "Equity Agreements") pursuant to which Gilead made the Initial Purchase at the Initial Purchase Price, the Second Purchase at the Second Purchase Price, the Third Purchase at the Third Purchase Price and the Fourth Purchase at the Fourth Purchase Price.  Gilead also has the right, at its option, to purchase additional shares from the Issuer, up to a maximum of 35% of the Issuer's then-outstanding Common Stock, from time to time for a period of five years from the closing of the Initial Purchase, at a purchase price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) at the time Gilead exercises such option and the Initial Purchase Price.  The Equity Agreements also include standstill and lock-up provisions and provide Gilead with certain other stock purchase and registration rights, as well as the right to designate three individuals to be appointed to the Issuer's board of directors.  &#13;
 &#13;
	In connection with the Public Offering, Gilead entered into a customary lock-up agreement (the "Lock-Up Agreement") with the representatives of the underwriters. The Lock-Up Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.&#13;
&#13;
	The acquisitions by the Reporting Person of the Issuer's securities as described herein were effected in connection with entry into the Collaboration Agreement and the Equity Agreements, and because of the belief that the securities of the Issuer represent an attractive investment. The foregoing description of the Equity Agreements is not complete and is subject to and qualified in its entirety by reference to the full text of such agreements.  The Third Amended and Restated Purchase Agreement and the Amended and Restated Investor Rights Agreement were filed previously as Exhibits 99.1 and 99.2, respectively, to the Amendment No. 3 to Schedule 13D filed by the Reporting Person with the SEC on January 31, 2024.&#13;
&#13;
	Except as otherwise described herein, the Reporting Person currently has no plan(s) or proposal(s) that relate to, or would result in, any of the events or transactions described in Item 4(a) through (j) of Schedule 13D, although the Reporting Person reserves the right, at any time and from time to time, to review or reconsider such position and/or change such purpose and/or formulate plans or proposals with respect thereto. &#13;
&#13;
	The Reporting Person intends to review from time to time its investment in the Issuer and the Issuer's business affairs, financial position, performance and other investments considerations. The Reporting Person may from time to time engage in discussions with the Issuer, its directors and officers, other stockholders of the Issuer and other persons on matters that relate to the management, operations, business, assets, capitalization, financial condition, strategic plans, governance and the future of the Issuer and/or its subsidiaries. Based upon such review and discussions, as well as general economic, market and industry conditions and prospects and the Reporting Person's liquidity requirements and investment considerations, and subject to the limitations in the agreements described above, the Reporting Person may consider additional courses of action, which may include, in the future, formulating plans or proposals regarding the Issuer and/or its subsidiaries, including possible future plans or proposals concerning events or transactions of the kind described in Item 4(a) through (j) of Schedule 13D.</transactionPurpose>
</item4>
<item5>
<percentageOfClassSecurities>Number of shares of Common Stock beneficially owned:&#13;
	Gilead - 39,691,649 shares&#13;
	Jeffrey A. Bluestone - 7,000 shares&#13;
&#13;
	Percent of class:&#13;
	Gilead - 35%&#13;
	Jeffrey A. Bluestone - 0.01%&#13;
&#13;
	The number of shares of Common Stock beneficially owned by Gilead consists of (i) 2,200,000 shares of Common Stock purchased in the 2020 Public Offering, (ii) the initial purchase of 5,963,029 shares of Common Stock pursuant to the Purchase Agreement, (iii) the subsequent purchase of 5,650,000 shares of Common Stock pursuant to the Amended and Restated Purchase Agreement, (iv) the subsequent purchase of 1,010,000 shares of Common Stock pursuant to the Second Amended and Restated Purchase Agreement, (v) the subsequent purchase of 15,238,095 shares of Common Stock pursuant to the Third Amended and Restated Purchase Agreement, (vi) the subsequent purchase of 1,363,636 shares of Common Stock pursuant to the Public Offering, and (vii) 8,266,889 Option Shares. The number of shares of Common Stock beneficially owned by Mr. Bluestone consists of options to purchase 7,000 shares of Common Stock exercisable within 60 days.&#13;
&#13;
	The percentage ownership for Gilead was calculated based upon 113,404,713 shares of common stock of the Issuer issued and outstanding, based on 105,137,824 shares of Common Stock issued and outstanding upon the closing of the Public Offering, as disclosed in the Prospectus Supplement, and assuming the immediate exercise in full by Gilead of its option to purchase the Option Shares. The percentage ownership for Mr. Bluestone was calculated based upon 105,144,824 shares of Common Stock issued and outstanding, based on 105,137,824 shares of Common Stock issued and outstanding upon the closing of the Public Offering, as disclosed in the Prospectus Supplement, and assuming the immediate exercise in full by Mr. Bluestone of his options.&#13;
&#13;
	To the best knowledge of the Reporting Person, none of the individuals listed on Schedule I beneficially owns any of the Issuer's Common Stock, except Mr. Bluestone, who has received options to purchase shares of Common Stock in partial payment for his service on the Issuer's Scientific Advisory Board.</percentageOfClassSecurities>
<numberOfShares>Number of shares as to which such person has:&#13;
&#13;
(i) Sole power to vote or to direct the vote:&#13;
	Gilead - 39,691,649 shares&#13;
	Jeffrey A. Bluestone - 7,000 shares&#13;
&#13;
(ii) Shared power to vote or to direct the vote:&#13;
	Gilead - 0 shares&#13;
	Jeffrey A. Bluestone - 0 shares&#13;
&#13;
(iii) Sole power to dispose or to direct the disposition of:&#13;
	Gilead - 39,691,649 shares&#13;
	Jeffrey A. Bluestone - 7,000 shares&#13;
&#13;
(iv) Shared power to dispose or to direct the disposition of:&#13;
	Gilead - 0 shares&#13;
	Jeffrey A. Bluestone - 0 shares</numberOfShares>
<transactionDesc>Except as reported in this Schedule 13D, neither the Reporting Person nor, to the best knowledge of the Reporting Person, any of the individuals listed on Schedule I have effected any transactions in the Common Stock during the past sixty (60) days.</transactionDesc>
<listOfShareholders>Not applicable.</listOfShareholders>
<date5PercentOwnership>Not applicable.</date5PercentOwnership>
</item5>
<item6>
<contractDescription>Except as disclosed in Items 3 and 4 of this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) to which the Reporting Person is a party with respect to the securities of the Issuer.</contractDescription>
</item6>
<item7>
<filedExhibits>Exhibit 99.1 Lock-Up Agreement dated February 17, 2025</filedExhibits>
</item7>
</items1To7>
<signatureInfo>
<signaturePerson>
<signatureReportingPerson>GILEAD SCIENCES, INC.</signatureReportingPerson>
<signatureDetails>
<signature>/s/ Andrew D. Dickinson</signature>
<title>Andrew D. Dickinson, Executive Vice President and Chief Financial Officer</title>
<date>03/05/2025</date>
</signatureDetails>
</signaturePerson>
</signatureInfo>
</formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>2
<FILENAME>schedulei.htm
<DESCRIPTION>SCHEDULE I
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: 2004
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; line-height: 11.4pt; font-family: 'Times New Roman',serif; font-size: 11pt; font-weight: bold;">Schedule I</div>
    <div style="line-height: 11.4pt; font-size: 11pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="text-indent: 36pt; line-height: 11.4pt; font-family: 'Times New Roman';">The name and present principal occupation of each of the executive officers and directors of Gilead Sciences, Inc. are set
      forth below.&#160; Unless otherwise noted, each of these persons have as their business address c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404.</div>
    <div style="line-height: 11.4pt; font-family: 'Times New Roman';">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z007b4dfec57b4d7d8a2f2ba56b30d6a0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 25%; vertical-align: middle; background-color: rgb(217, 217, 217); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; line-height: 11.4pt;">Name</div>
          </td>
          <td style="width: 25%; vertical-align: middle; background-color: rgb(217, 217, 217); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; line-height: 11.4pt;">Title</div>
          </td>
          <td style="width: 25%; vertical-align: middle; background-color: rgb(217, 217, 217); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; line-height: 11.4pt;">Citizenship</div>
          </td>
          <td style="width: 25%; vertical-align: middle; background-color: rgb(217, 217, 217); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="text-align: center; line-height: 11.4pt;">Principal Occupation and, if not employed by Gilead Sciences, Inc., Name, Principal Business and Address of Employer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Daniel P. O&#8217;Day</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Chief Executive Officer, Chairman and Director</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Jacqueline K. Barton, Ph.D.</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Director</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Professor Emerita, California Institute of Technology</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Jeffrey A. Bluestone, Ph.D.</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Director</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">
              <div style="line-height: 10.25pt;">President and Chief Executive Officer, Sonoma Biotherapeutics, Inc.</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Sandra J. Horning, M.D.</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Director</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Retired Chief Medical Officer of Roche, Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Kelly A. Kramer</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Director</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Retired Executive Vice President and Chief Financial Officer, Cisco Systems, Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Ted W. Love, M.D.</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Director</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="line-height: 11.4pt; font-family: 'Times New Roman';">Chair of Board of</div>
            <div style="line-height: 11.4pt; font-family: 'Times New Roman';">Directors, Biotechnology</div>
            <div style="line-height: 11.4pt; font-family: 'Times New Roman';">Innovation Organization</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Harish Manwani</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Director</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Singapore</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Senior Operating Partner, Blackstone</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Javier J. Rodriguez</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Director</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Mexico</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Chief Executive Officer, DaVita, Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Anthony Welters</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Director</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">
              <div style="line-height: 12.55pt;">Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Andrew D. Dickinson</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Chief Financial Officer</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Johanna Mercier</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Chief Commercial Officer</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Dietmar Berger, M.D., Ph.D.</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Chief Medical Officer</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">*</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Deborah H. Telman</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">Executive Vice President, Corporate Affairs and General Counsel</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">United States</div>
          </td>
          <td style="width: 25%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-family: 'Times New Roman';">
            <div style="line-height: 11.4pt;">*</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 11.4pt; font-family: 'Times New Roman';"> <br>
    </div>
    <div style="line-height: 11.4pt; font-family: 'Times New Roman';">* The present principal occupation for each of these individuals is officer of Gilead Sciences, Inc. and officer, trustee and/or director of
      other affiliated entities.</div>
    <div style="line-height: 11.4pt; font-family: 'Times New Roman';">&#160;</div>
    <div style="line-height: 11.4pt;"><br style="line-height: 11.4pt;">
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>lockupagreement.htm
<DESCRIPTION>LOCK-UP AGREEMENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: 2004
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;">
    <div style="line-height: 11.4pt; font-family: 'Times New Roman'; font-weight: bold;">Exhibit 99.1</div>
    <div style="line-height: 11.4pt; font-family: Arial, sans-serif; font-weight: bold;"> <font style="font-family: 'Times New Roman'; font-weight: bold; font-size: 11pt;"><br>
      </font></div>
    <div style="text-align: center; line-height: 11.4pt; font-family: Arial,sans-serif; font-weight: bold;"><font style="font-family: 'Times New Roman'; font-weight: bold; font-size: 11pt;"> </font>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: bold;">Arcus Biosciences, Inc.</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: bold; font-size: 11pt;">&#160;</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: bold;">Lock-Up Agreement</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: bold; font-size: 11pt;">&#160;</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: bold;">February 17, 2025</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: bold; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">Goldman Sachs &amp; Co. LLC</div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">Leerink Partners LLC</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><br style="line-height: 12.55pt;">
      </div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">As Representatives of the several Underwriters</div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">named in Schedule I to the Underwriting Agreement</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><br style="line-height: 12.55pt;">
      </div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">c/o Goldman Sachs &amp; Co. LLC</div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">200 West Street</div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">New York, NY&#160; 10282-2198</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">c/o Leerink Partners LLC</div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">53 State St</div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">Boston, MA 02110</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><br style="line-height: 12.55pt;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z17c8b8ec94a343e08721e21e8ba659d3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">Re:</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">
              <div><u>Arcus Biosciences, Inc. - Lock-Up Agreement</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">To the addressees set forth above:</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">The undersigned understands that you, as representatives (the &#8220;Representatives&#8221;), propose to
        enter into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) on behalf of the several Underwriters named in Schedule I to such agreement (collectively, the &#8220;Underwriters&#8221;), with Arcus Biosciences, Inc., a Delaware corporation (the
        &#8220;Company&#8221;), providing for an offering (the &#8220;Offering&#8221;) of shares (the &#8220;Shares&#8221;) of the common stock, par value $0.0001 per share, of the Company (the &#8220;Common Stock&#8221;) pursuant to a Registration Statement on Form S-3 (the &#8220;Registration Statement&#8221;)
        filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">In consideration of the agreement by the Underwriters to offer and sell the Shares, and of
        other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning from the date of this Lock-Up Agreement and continuing to and including the date 60 days
        after the date of the final prospectus relating to the Offering (the &#8220;Prospectus&#8221;) (such period, the &#8220;Lock-Up Period&#8221;), the undersigned shall not, and shall not cause or direct any of its affiliates to, (i) offer, sell, contract to sell, pledge,
        grant any option, right or warrant to purchase, purchase any option or contract to sell, lend or otherwise transfer or dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or any securities
        convertible into, exchangeable for or that represent the right to receive shares of Common Stock (such shares of Common Stock, options, rights, warrants or other securities, collectively, &#8220;Lock-Up Securities&#8221;), including without limitation any such
        Lock-Up Securities now owned or hereafter acquired by the undersigned, (ii) engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option,
        or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition
        (whether by the undersigned or someone other than the undersigned), or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement
        (or instrument provided for thereunder) would be settled by delivery of Common Stock or other securities, in cash or otherwise (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a &#8220;Transfer&#8221;), (iii) make any
        demand for or exercise any right with respect to the registration of any Lock-Up Securities or (iv) otherwise publicly announce any intention to engage in or cause any action, activity, transaction or arrangement described in clause (i), (ii) or
        (iii) above. The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement that provides for, is designed to or
        reasonably could be expected to lead to or result in any Transfer during the Lock-Up Period.</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">Notwithstanding the foregoing, the undersigned may:</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z4a7ce677606643d49e7aaa594e9fd9cd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 11pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">(a)</div>
                <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">transfer the undersigned&#8217;s Lock-Up Securities (i) as one or more <font style="font-style: italic;">bona
                    fide</font> gifts or charitable contributions, or for <font style="font-style: italic;">bona fide</font> estate planning purposes, (ii) upon death by will, testamentary document or intestate succession, (iii) if the undersigned is a
                  natural person, to any member of the undersigned&#8217;s immediate family (for purposes of this Lock-Up Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more
                  remote than first cousin) or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned or, if the undersigned is a trust, to a trustor or beneficiary of the trust or the estate of a
                  beneficiary of such trust, (iv) to a partnership, limited liability company or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity
                  securities or similar interests, (v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (a)(i) through (iv) above, (vi) if the undersigned is a corporation, partnership,
                  limited liability company or other business entity, (A) to another corporation, partnership, limited liability company or other business entity that is an affiliate (as defined in Rule 405 under the Securities Act of 1933, as amended) of
                  the undersigned, or to any investment fund or other entity which fund or entity is controlled or managed by the undersigned or affiliates of the undersigned, or (B) as part of a distribution by the undersigned to its stockholders,
                  partners, members or other equityholders or to the estate of any such stockholders, partners, members or other equityholders, (vii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or
                  separation agreement, (viii) to the Company from an employee of the Company upon death, disability or termination of employment, in each case, of such employee, (ix) if the undersigned is not an officer or director of the Company, in
                  connection with a sale of the undersigned&#8217;s shares of Common Stock acquired (A) from the Underwriters in the Offering or (B) in open market transactions after the closing date of the Offering, (x) to the Company in connection with the
                  vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221; exercise) that are scheduled to expire or
                  automatically vest during the Lock-Up Period, including any transfer to the Company for the payment of tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such restricted stock units, options,
                  warrants or other rights, or in connection with the conversion of convertible securities, in all such cases pursuant to equity awards granted under a stock incentive plan or other equity award plan, or pursuant to the terms of convertible
                  securities, each as described in the Registration Statement, the preliminary prospectus relating to the Shares included in the Registration Statement immediately prior to the time the Underwriting Agreement is executed and the Prospectus,
                  provided that any securities received upon such vesting, settlement, exercise or conversion shall be subject to the terms of this Lock-Up Agreement, or (xi) with the prior written consent of the Representatives on behalf of the
                  Underwriters; provided that (A) in the case of clauses (a)(i), (ii), (iii), (iv), (v) and (vi) above, such transfer or distribution shall not involve a disposition for value, (B) in the case of clauses (a)(i), (ii), (iii), (iv), (v), (vi)
                  and (vii) above, it shall be a condition to the transfer or distribution that the donee, devisee, transferee or distributee, as the case may be, shall sign and deliver a lock&#8209;up agreement in the form of this Lock-Up Agreement, (C) in the
                  case of clauses (a)(ii), (iii), (iv), (v) and (vi) above, no filing by any party (including, without limitation, any donor, donee, devisee, transferor, transferee, distributor or distributee) under the Securities Exchange Act of 1934, as
                  amended (the &#8220;Exchange Act&#8221;), or other public filing, report or announcement reporting a reduction in beneficial ownership of Lock-Up Securities shall be required or shall be voluntarily made in connection with such transfer or
                  distribution, and (D) in the case of clauses (a)(i), (vii), (viii), (ix) and (x) above, no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made, and if any such filing, report or
                  announcement shall be legally required during the Lock-Up Period, such filing, report or announcement shall clearly indicate in the footnotes thereto (A) the circumstances of such transfer or distribution and (B) in the case of a transfer
                  or distribution pursuant to clauses (a)(i) or (vii) above, that the donee, devisee, transferee or distributee has agreed to be bound by a lock-up agreement in the form of this Lock-Up Agreement;</div>
                <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="za961cd3c5dfd44d997243716a2aa8792" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">
                <div style="text-align: left; margin-left: 36pt; line-height: 12.55pt;">(b)</div>
              </td>
              <td style="width: auto; vertical-align: top; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">
                <div style="text-align: justify; line-height: 12.55pt;">(i) transfer, sell or other dispose of the undersigned&#8217;s Lock-Up Securities pursuant to a written plan, existing as of the date hereof, meeting the requirements of Rule 10b5-1 under
                  the Exchange Act, provided that any filing made under the Exchange Act in connection therewith shall state that such sales were made pursuant to a written plan meeting the requirements of Rule 10b5-1 under the Exchange Act, or (ii) enter
                  into a written plan meeting the requirements of Rule 10b5-1 under the Exchange Act relating to the transfer, sale or other disposition of the undersigned&#8217;s Lock-Up Securities, if then permitted by the Company, provided that none of the
                  securities subject to such plan may be transferred, sold or otherwise disposed of until after the expiration of the Lock-Up Period and no public announcement, report or filing under the Exchange Act, or any other public filing, report or
                  announcement, shall be voluntarily made (whether by or on behalf of the undersigned, the Company or any other party) regarding, or that otherwise discloses, the establishment of such plan during the Lock-Up Period, and if any such filing,
                  report or announcement shall be legally required during the Lock-Up Period, such filing, report or announcement shall clearly indicate that that none of the securities subject to such plan may be transferred, sold or otherwise disposed of
                  pursuant to such plan until after the expiration of the Lock-Up Period; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><br style="line-height: 12.55pt;">
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z690d742505184442acd296d5d666180d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 11pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">(c)</div>
                <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">transfer the undersigned&#8217;s Lock-Up Securities pursuant to a bona fide third-party tender offer, merger,
                  consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company&#8217;s capital stock involving a Change of Control of the Company (for purposes hereof, &#8220;Change of
                  Control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock
                  if, after such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company (or the surviving entity)); provided that in the event that such tender offer, merger,
                  consolidation or other similar transaction is not completed, the undersigned&#8217;s Lock-Up Securities shall remain subject to the provisions of this Lock-Up Agreement.</div>
                <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">If the undersigned is an officer or director of the Company, the undersigned further agrees
        that the foregoing provisions shall be equally applicable to any issuer-directed or other Shares the undersigned may purchase in the Offering.</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">If the undersigned is not a natural person, the undersigned represents and warrants that no
        single natural person, entity or &#8220;group&#8221; (within the meaning of Section 13(d)(3) of the Exchange Act), other than a natural person, entity or &#8220;group&#8221; (as described above) that has executed a Lock-Up Agreement in substantially the same form as this
        Lock-Up Agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned.</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">The undersigned now has, and, except as contemplated by clauses (a) and (c) of the third
        paragraph of this Lock-Up Agreement, for the duration of this Lock-Up Agreement will have, good and marketable title to the undersigned&#8217;s Lock-Up Securities, free and clear of all liens, encumbrances and claims whatsoever. The undersigned also
        agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer agent and registrar against the transfer of the undersigned&#8217;s Lock-Up Securities except in compliance with the foregoing restrictions.</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">The undersigned acknowledges and agrees that none of the Underwriters has made any
        recommendation or provided any investment or other advice to the undersigned with respect to this Lock-Up Agreement or the subject matter hereof, and the undersigned has consulted its own legal, accounting, financial, regulatory, tax and other
        advisors with respect to this Lock-Up Agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may have provided or hereafter
        provide to the undersigned in connection with the Offering a Form CRS and/or certain other disclosures as contemplated by Regulation Best Interest, the Underwriters have not made and are not making a recommendation to the undersigned to enter into
        this Lock-Up Agreement or to transfer, sell or dispose of, or to refrain from transferring, selling or disposing of, any shares of Common Stock, and nothing set forth in such disclosures or herein is intended to suggest that any Underwriter is
        making such a recommendation.</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">This Lock-Up Agreement shall automatically terminate and the undersigned shall be released from
        all of his, her or its obligations hereunder upon the earlier of (i) the date on which the Registration Statement filed with the SEC with respect to the Offering is withdrawn, (ii) the date on which for any reason the Underwriting Agreement is
        terminated (other than the provisions thereof that survive termination) prior to payment for and delivery of the Shares to be sold thereunder (other than pursuant to the Underwriters&#8217; option thereunder to purchase additional Shares), (iii) the date
        on which the Company notifies the Representatives, in writing and prior to the execution of the Underwriting Agreement, that it does not intend to proceed with the Offering and (iv) March 31, 2025, in the event that the Underwriting Agreement has
        not been executed by such date (provided, however, that the Company may, by written notice to the undersigned prior to such date, extend such date by a period of up to an additional 90 days).</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">The undersigned understands that the Company and the Underwriters are relying upon this Lock-Up
        Agreement in proceeding toward consummation of the Offering. The undersigned further understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned&#8217;s heirs, legal representatives, successors and assigns. The
        undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of New York,
        without regard to principles of conflict of laws that would result in the application of any law other than the laws of the State of New York. This Lock-Up Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic
        signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
        effective for all purposes.</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: right; margin-right: 157.5pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">Very truly yours,</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><br style="line-height: 12.55pt;">
      </div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf46abab7cb624229a1d47083c884104e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.6%; vertical-align: top; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">
              <div style="line-height: 12.55pt;">IF AN INDIVIDUAL:</div>
            </td>
            <td style="width: 50.4%; vertical-align: top; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">
              <div style="line-height: 12.55pt;">IF AN ENTITY:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.6%; vertical-align: top;">
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt;"><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">By:</font><font class="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 11pt; font-family: 'Times New Roman'; font-weight: normal;">&#160; _________________________________ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;"><font class="TRGRRTFtoHTMLTab" style="text-indent: 0px;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-style: italic;">(duly authorized signature)</font></font></div>
            </td>
            <td style="width: 50.4%; vertical-align: top;">
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt;"><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;"><u>Gilead Sciences, Inc. &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</u></font><font class="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 11pt; font-family: 'Times New Roman'; font-weight: normal;"> </font><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;"><font style="font-style: italic;"></font></font></div>
              <div style="line-height: 12.55pt;"><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;"><font style="font-style: italic;">(please print complete name of entity)</font></font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.6%; vertical-align: top;">
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt;"><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">Name:</font><font class="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 11pt; font-family: 'Times New Roman'; font-weight: normal;">________________________________ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;"><font class="TRGRRTFtoHTMLTab" style="text-indent: 0px;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-style: italic;">(please print full name)</font></font></div>
            </td>
            <td style="width: 50.4%; vertical-align: top;">
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt;"><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">By:</font><font class="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 11pt; font-family: 'Times New Roman'; font-weight: normal;"> </font><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;"><u>/s/ Hiro Koizumi&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160;&#160;&#160;&#160;&#160; </u><br>
                  <font class="TRGRRTFtoHTMLTab" style="text-indent: 0px;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-style: italic;">(duly authorized signature)</font></font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.6%; vertical-align: top; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</td>
            <td style="width: 50.4%; vertical-align: top;">
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt;"><font style="font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">Name: <u>Hiro Koizumi&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u><br>
                  <font class="TRGRRTFtoHTMLTab" style="text-indent: 0px;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-style: italic;">(please print full name)</font></font></div>
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><font style="line-height: 12.55pt;">&#160;</font></div>
              <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-weight: normal;">Title: <u>Vice President, Alliance Management&#160;&#160;&#160;&#160;&#160; <br>
                </u></div>
              <div style="text-indent: 54pt; line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-style: italic; font-weight: normal;">(please print full title)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><br style="line-height: 12.55pt;">
      </div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><br style="line-height: 12.55pt;">
      </div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;"><br style="line-height: 12.55pt;">
      </div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-weight: normal; font-size: 11pt;">&#160;</div>
      <div style="line-height: 12.55pt; font-family: 'Times New Roman'; font-size: 11pt; font-style: italic; font-weight: normal;">[Signature Page to Lock-Up Agreement]</div>
      <div style="line-height: 12.55pt">&#160;</div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
